Empagliflozin

  • Sumari Davis Amayeza Information Services
Keywords: Empagliflozin, Type 2 Diabetes

Abstract

Glucose-lowering agents in the management of type 2 diabetes have targeted various organs including the pancreas, liver, muscle cells, adipose tissue and the gut. The latest addition to the armament of treatment options are the sodium-glucose cotransporter 2 (SGLT2) inhibitors, targeting the kidney, which plays a central role in glucose homeostasis.1 Empaglifozin has been shown to be effective in reducing haemoglobin A1c HbA1c), with the additional benefits of weight loss, blood pressure reductions, improved renal outcomes and a reduction in the risk of cardiovascular death.2

Author Biography

Sumari Davis, Amayeza Information Services
BPharm, Amayeza Information Services
Published
2019-02-27
Section
Focus on ...